Bupivacain is one of 294 small molecule programs targeting Rib Fracture. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
2828 competitors in Breast Cancer
Bupivacain
Adriamycin
Gemzar
Methylthioninium Chloride
Aquasol E
Perflutren Lipid Microsphere
Diuretic
Naltrexone/bupropion
Iniparib
QBX258
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Serratus Anterior Plane Block
NCT06856538
Genicular Nerve Block
NCT06639503
Dexmedetomidine
NCT06668220
Mastectomy
NCT06574022
Liposomal Bupivacaine
NCT05972018
Sternotomy
NCT04985500
Clinical
Sources
Details